• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Molecular Profiles joins consortium to drive pediatric formulation development

Molecular Profiles joins consortium to drive pediatric formulation development

January 2, 2014
CenterWatch Staff

A collaborative pharmaceutical project focused on improving the pathway for developing pediatric formulations has been given the go-ahead after successfully securing an innovation grant.

The U.K.-wide consortium, led by AstraZeneca, received a $1.1 million grant from the U.K.’s innovation agency, the Technology Strategy Board, to help fund a $1.6 million project aimed at accelerating pediatric formulation development through smart design and predictive science.

The consortium is comprised of pharmaceutical analytical development specialist Molecular Profiles, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline and academic institutions including University College London, University of Bath, University of Birmingham, Aston University and the nonprofit Academy of Pharmaceutical Sciences.

Pediatric formulation development is more complex than the associated adult medicines. In addition to considering the differences in physiology and anatomy, pediatric formulations must offer flexible dosing and provide effective taste-masking.

This project will address the need to improve the speed, cost and quality of pediatric formulation development by drawing on the combined experience of the consortium members. The goal is to deliver a novel, commercially available, regulatory-approved platform to identify the most appropriate delivery strategy.

The government-backed Technology Strategy Board has awarded over $15.2 million to support 35 collaborative projects to advance the U.K.’s capabilities in formulated products. The funding allocated through the Formulated products—meeting the product and process design challenge was shared across 19 feasibility projects and 16 collaborative R&D projects. The initial funding was increased by 50% due to the strength of submissions.

Molecular Profiles works with pharmaceutical companies across the globe and specializes in advanced characterization, R&D, formulation development and clinical manufacturing services.

Upcoming Events

  • 12Apr

    The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing